We are happy to announce that our team is growing. Warm welcome to our R&D, marketing, business development, HR and office admin team members! We are looking forward to build
Glycanostics has become a member of the Oslo Cancer Cluster (OCC), an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of
Applications that meet all the criteria but are not recommended for funding due to budget limitations will be awarded a Seal of Excellence to help them secure funding from other
Glycanostics has been selected as one of 65 innovative start-ups and SMEs out of more than 4,000 applicants to receive funding under the European Innovation Council (EIC) Accelerator scheme. Glycanostics became
Another important milestone achieved by the Glycanostics team! Via the Crowdberry Investment Platform, we presented our highly accurate diagnostic test to private investors in September 2021 and raised an additional
On Monday 21st June , our CEO Eva Kováčová (on the right) together with CSO Jan Tkac (on the left) had the great honour to introduce the company Glycanostics to the President of the EC,
Glycanostics and Crowdberry Investment Management took an important step towards achieving its vision. On Friday 7th May 2021 we signed an investment agreement to gain key resources of €310,000 for
We are an innovative start-up company ready to
reimagine medicine via early stage, highly accurate and unique cancer diagnostics